Innovative Patient Care

At Janssen, everything we do begins with innovation; it is at the very heart of our business.

We believe there are no limits to what science can do. In our search for the solutions to the medical challenges of our time, we have consistently invested 11 per cent of our global sales in research and development.

We have a strong record in discovering new treatments and making them available to patients: In 2012 the InnoThink Center for Research recognized Janssen’s world-class discovery and development achievements and named us the Most Productive Pharmaceutical Company.

But we don’t stop here: We plan to bring 10 major new pharmaceutical products to our patients worldwide. Furthermore we are researching new uses for our existing medicines, with up to 25 new indications planned between 2013 and 2017.

Key to our research success is our focus on collaboration: We believe in connecting our own expertise with that of others, seeking the top minds in every field: from academia, biotech and other pharmaceutical companies. Together we can work more effectively.

Janssen comprises companies with nearly 40,000 employees in more than 150 countries around the world. We work within and beyond our communities, globally, to bring innovative treatments for serious unmet medical needs. We make extraordinary efforts to help people enjoy ordinary moments.

Today’s medical challenges are far more complex than ever before. Yet it’s not just about finding new treatments. We look at these medical challenges in a broader context. We go beyond the medicine – ensuring people have the information, education and support to access the treatments they need and use them correctly for the best possible results. Helping people live full and happy lives inspires us. And promising new science and technology spur us on.

It all comes back to our commitment to collaboration, in research and education, all the way to patient access. We won’t stop until new ideas turn into medical solutions for patients in need.

With our unique model of innovation, Janssen has built an industry-leading pipeline. Worldwide, the Janssen pharmaceutical companies of Johnson & Johnson have had 20 consecutive quarters of operational sales growth, as reported on April 14, 2015.

We are actively developing treatments for patients in five important therapeutic areas of healthcare:

• Metabolic Diseases
• Immunology
• Infectious Diseases
• Neuroscience
• Oncology

Through extensive medical research our solutions may be able to alleviate, contain or cure some of the world’s most serious conditions and diseases.

The need for new and even more effective drugs is greater than ever. But there is also a need for preventive treatments for diseases, diagnostics to discover diseases at the earliest stage possible, and biomarkers to distinguish between the various sub-types of a disease.

Forgetting to take your pills can affect how well they work. Recent advances in drug delivery are helping to overcome this problem. Medicines that slowly release their drug over 24 or even 72 hours can transform the lives of patients because they don’t have to remember to take multiple tablets daily to stop their symptoms from returning.

Which medicine works best for you? In the future we could possibly use biomarkers in your blood to catch your illness at the earliest possible stage. Our knowledge about diseases (precise causes and specific sub-types) and genes is growing every day. Based on the diagnosis of your specific disease and your unique genetic profile, we might then be able to tailor the medicines that will be most effective for you.